Study of APH-1105 in Patients With Mild to Moderate Alzheimer's Disease

PHASE2UnknownINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

December 31, 2024

Conditions

DementiaAlzheimer Disease 1Alzheimer Disease 2Alzheimer Disease 3

Interventions

DRUG

APH-1105

The investigational drug product, APH-1105 is a sterile, pyrogen-free lyophilized powder intended for intranasal administration.

OTHER

Placebo

The placebo is a sterile, pyrogen free lyophilized powder identical in appearance to the experimental drug